Angitia Biopharmaceuticals

Angitia Biopharmaceuticals secures $130 million in Series D funding. The round is co-led by Frazier Life Sciences and Venrock Healthcare Capital Partners, with contributions from both new and existing investors. The capital will advance the company’s biopharmaceutical development pipeline.

Feb 2026GlobeNewswireNews article

Angitia Biopharmaceuticals finishes enrolling 379 postmenopausal women with osteoporosis in its Phase 2 **ARTEMIS** trial of the experimental therapy **AGA2118**. The study evaluates the drug’s dual-target mechanism for treating osteoporosis. The company now proceeds to the trial’s efficacy and safety assessment phase.

Jan 2026MedPath TrialNews article

Angitia secures $120 million in funding to develop osteoporosis treatments. The company is conducting a clinical trial of its osteoporosis drug in postmenopausal women at high risk of fractures. The trial aims to evaluate the drug’s safety and efficacy in this patient population.

Dec 2024Longevity.TechnologyNews article

Angitia Biopharmaceuticals secures **$120 million in Series C funding** to advance therapeutics for serious musculoskeletal diseases. Bain Capital Life Sciences leads the round, joined by new investor Janus Henderson and returning backers OrbiMed, 3H Health Investment, Yonghua Capital, and Legend Capita. The company remains focused on clinical-stage drug discovery in this specialized medical field.

Dec 2024baincapital.comNews article